TWI848905B - 用於治療補體介導之疾病及病症之方法 - Google Patents

用於治療補體介導之疾病及病症之方法 Download PDF

Info

Publication number
TWI848905B
TWI848905B TW107108658A TW107108658A TWI848905B TW I848905 B TWI848905 B TW I848905B TW 107108658 A TW107108658 A TW 107108658A TW 107108658 A TW107108658 A TW 107108658A TW I848905 B TWI848905 B TW I848905B
Authority
TW
Taiwan
Prior art keywords
antibody
seq
amino acid
acid sequence
region
Prior art date
Application number
TW107108658A
Other languages
English (en)
Chinese (zh)
Other versions
TW201842931A (zh
Inventor
彼得 佛拉瑟
格雷厄姆 帕里
南希 斯塔利亞諾
聖帝普 帕尼克爾
Original Assignee
美商生物維瑞提夫美國公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商生物維瑞提夫美國公司 filed Critical 美商生物維瑞提夫美國公司
Publication of TW201842931A publication Critical patent/TW201842931A/zh
Application granted granted Critical
Publication of TWI848905B publication Critical patent/TWI848905B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW107108658A 2017-03-14 2018-03-14 用於治療補體介導之疾病及病症之方法 TWI848905B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762471190P 2017-03-14 2017-03-14
US62/471,190 2017-03-14
US201762553059P 2017-08-31 2017-08-31
US62/553,059 2017-08-31

Publications (2)

Publication Number Publication Date
TW201842931A TW201842931A (zh) 2018-12-16
TWI848905B true TWI848905B (zh) 2024-07-21

Family

ID=61873979

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107108658A TWI848905B (zh) 2017-03-14 2018-03-14 用於治療補體介導之疾病及病症之方法
TW113122096A TW202513092A (zh) 2017-03-14 2018-03-14 用於治療補體介導之疾病及病症之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113122096A TW202513092A (zh) 2017-03-14 2018-03-14 用於治療補體介導之疾病及病症之方法

Country Status (14)

Country Link
US (1) US20210115116A1 (cg-RX-API-DMAC7.html)
EP (1) EP3596121A1 (cg-RX-API-DMAC7.html)
JP (3) JP7293122B2 (cg-RX-API-DMAC7.html)
KR (2) KR102934707B1 (cg-RX-API-DMAC7.html)
CN (1) CN110753701A (cg-RX-API-DMAC7.html)
AU (2) AU2018236267B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019018950A2 (cg-RX-API-DMAC7.html)
CA (1) CA3055781A1 (cg-RX-API-DMAC7.html)
CR (1) CR20190468A (cg-RX-API-DMAC7.html)
IL (2) IL269174B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019010994A (cg-RX-API-DMAC7.html)
SG (1) SG11201907583TA (cg-RX-API-DMAC7.html)
TW (2) TWI848905B (cg-RX-API-DMAC7.html)
WO (1) WO2018170145A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
ES2912396T3 (es) 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
EP4212175A1 (en) 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
IL326479A (en) 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
PL3893924T3 (pl) 2018-12-13 2025-01-13 argenx BV Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
JP2023503611A (ja) * 2019-11-26 2023-01-31 オメロス コーポレーション 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法
FI129383B (en) 2020-06-15 2022-01-31 Faron Pharmaceuticals Oy Stable anti-clever-1 antibody formulation
BR112023001942A2 (pt) * 2020-08-06 2023-02-28 Bioverativ Usa Inc Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento
TW202304508A (zh) 2021-03-31 2023-02-01 美商百歐維拉提夫美國公司 減少冷凝集素疾病患者之手術相關溶血
US12252550B2 (en) 2021-05-20 2025-03-18 Dianthus Therapeutics Opco, Inc. Antibodies that bind to C1S and uses thereof
CN117642431B (zh) 2021-07-13 2025-07-15 迈威(美国)生物治疗有限公司 抗c1s抗体和其用途
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
MA71249A (fr) 2022-06-24 2025-04-30 Bioverativ Usa Inc. Méthodes de traitement de maladies médiées par complément
TW202426490A (zh) 2022-11-21 2024-07-01 美商黛安瑟斯醫療運營公司 結合ｃ１ｓ之抗體及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884088A (zh) * 2012-11-02 2015-09-02 真北医疗股份有限公司 抗补体C1s抗体和其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
WO2015084999A1 (en) * 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884088A (zh) * 2012-11-02 2015-09-02 真北医疗股份有限公司 抗补体C1s抗体和其用途

Also Published As

Publication number Publication date
AU2025204392A1 (en) 2025-07-03
TW202513092A (zh) 2025-04-01
CN110753701A (zh) 2020-02-04
AU2018236267B2 (en) 2025-03-13
BR112019018950A2 (pt) 2020-04-22
JP2020511469A (ja) 2020-04-16
SG11201907583TA (en) 2019-09-27
TW201842931A (zh) 2018-12-16
US20210115116A1 (en) 2021-04-22
IL269174B1 (en) 2026-01-01
EP3596121A1 (en) 2020-01-22
IL269174A (en) 2019-11-28
WO2018170145A1 (en) 2018-09-20
MX2025010483A (es) 2025-10-01
JP2025072437A (ja) 2025-05-09
KR20260039796A (ko) 2026-03-20
KR102934707B1 (ko) 2026-03-06
JP7293122B2 (ja) 2023-06-19
KR20190128676A (ko) 2019-11-18
IL269174B2 (en) 2026-05-01
JP2023071824A (ja) 2023-05-23
CR20190468A (es) 2019-12-17
IL325084A (en) 2026-02-01
AU2018236267A1 (en) 2019-09-26
MX2019010994A (es) 2020-12-01
CA3055781A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
KR102934707B1 (ko) 보체-매개된 질환 및 장애의 치료 방법
JP2023026536A (ja) 補体のインヒビターによる発作性夜間血色素尿症患者の処置
AU2022215307B2 (en) Methods of treating autoimmune and alloimmune disorders
KR102553777B1 (ko) 다양한 질환 및 장애의 치료를 위해 masp-3을 억제하는 조성물 및 방법
AU2013337638B2 (en) Anti-complement C1s antibodies and uses thereof
JP2024105420A (ja) 免疫性血小板減少症を治療する組成物及び方法
CN104684929A (zh) 治疗血管疾病及其并发症
JP2020524696A (ja) Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
US20250145696A1 (en) Methods for treating complement-mediated diseases and disorders
WO2022081997A1 (en) Compositions and methods for treating blood disorders
HK40022920A (en) Methods for treating complement-mediated diseases and disorders
WO2025094976A1 (ja) ヘモジデリンの沈着及び／又は滑膜肥厚の改善又は抑制剤
NZ791361A (en) Engineered anti-il-2 antibodies
BR112018069283B1 (pt) Anticorpos monoclonais contra o sítio ativo de fator xi e usos dos mesmos
NZ728179A (en) Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders